Notably, the therapeutic potential of PIK3CA inhibitors—previously validated in PIK3CA-driven disorders like Klippel-Trenaunay syndrome and CLOVES syndrome (18)-highlights the need to clarify mutation-specific mechanisms in FAVA. This evidence concerns the gene PIK3CA and CLOVES syndrome.